Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening

In Vivo

Volumn 18, Issue 6, 2004, Pages 831-836

  Roupa, Zoi ^a,e   Faros, Efthimios ^b   Raftopoulos, Vasilios ^c   Tzavelas, Georgios ^d   Kotrotsiou, Evangelia ^a   Sotiropoulou, Penelope ^a   Karanikola, Evridiki ^a   Skifta, Evdoxia ^a   Ardavanis, Alexandros ^a  

^a High Technological Education Inst   (Greece)

^b GENERAL HOSPITAL OF LARISSA   (Greece)

^c Hellenic Centre for Infectious Diseases Control   (Greece)

^d UNIVERSITY OF WEST ATTICA   (Greece)

^e NONE   (Greece)

Author keywords

CA 125; Menopausal status; Ovarian cancer screening; Transvaginal ultrasonography

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; CANCER SCREENING; CASE CONTROL STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; OVARY CANCER; PILOT STUDY; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

EID: 11844294937     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics 1999. Ca-A Cancer J Clin 49 (1), 1999.
2. The Surveillance Program, Division of Cancer Prevention and Control. Cancer Statistics Review 1973-1987. Washington DC; National Cancer Institute, 1988.
3. Jacobs I, Stabile I, Bridges J et al: Multimodal approach to screening for ovarian cancer. Lancet 1: 268-71, 1988.
4. Jacobs I and Bast RC Jr: The CA125 tumor associated antigen: a review of the literature. Human Reprod 4: 1-12, 1989.
5. Skates SJ and Singer DE: Quantifying the potential benefit of CA125 screening for ovarian cancer. J Clin Epidemiol 44: 365-80, 1991.
6. Tamakoshi K, Kikkawa F, Shibata K et al: Clinical value of CA125, CA19-9, CEA, CA72-4 and TPA in borderline ovarian tumor. Gynecol Oncol 62(1): 67-72, 1996
7. Eagle K and Ledermann JA: Tumor markers in ovarian malignancies. Oncology 2: 324-329, 1997.
8. Crump C, McIntosh MW, Urbal N, Anderson G and Karlan BY: Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidem Biomark Prevent 9: 1107-1111, 2000.
9. Petricoin E, Ardekani A, Hitt B, Levine P et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-77, 2002.
10. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ and Jacobs I: Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidem Biomark Prevent 10: 489-493, 2001.
11. Niloff JM, Knapp RC, Schaetzl E et al: CA125 antigen levels in obstetric and gynaecologic patients. Obstet Gynecol 64(5 703-7, 1984.
12. Haga Y, Sakamoto K, Egami H, Yoshimura R and Akagi M: Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci 292(1): 25-9, 1986.
13. Schwartz PE and Taylor KJ: Is early detection of ovarian cancer possible? Ann Med 27(5): 519-28, 1995.
14. Shuiqing MA, Keng S and Jinghe L: A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J 116(3): 396-99, 2003.
15. Alagoz T, Butler RE, Berman M, Anderson B, Manetta A and DiSaia P: What is normal CA125 level? Gynecol Oncol 53(1): 93-7, 1994.
16. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG and Oram D: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306(6884): 1030-4, 1993.
17. Menon U and Jacobs IJ: Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 11(Suppl 1 3-6, 2001.
18. Einhorn N, Sjovall K, Knapp RC et al: Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynaecol 80(1): 14-18, 1992.
19. Gohagan JK, Prorok PC, Hayes RB and Kramer BS: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21(6 Suppl): 51S-272S, 2000.
20. McNeil C: Ovarian cancer screening trials in progress [news]. J Natl Cancer Inst 87: 1284, 1995.
21. Karlan BY: The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. Cancer Invest 15: 265-9, 1997.
22. Urban N: Screening for ovarian cancer. We now need a definite randomised trial. BMJ 319: 1317-8, 1999.
23. Jacobs I, Skates S, Davies A, Woolas R, Jeyerajah A, Weidemann P, Sibley K and Oram D: Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study. BMJ 313: 1355-58, 1996.
24. Jacobs I, Skates SJ, MacDonald N, Menon U, Rosenthal A and Prys DA: Outcome of a pilot randomized controlled trial of ovarian cancer screening. Lancet 253: 2107-10, 1999.
25. Bese T, Demirkiran F, Arvas M, Oz AU, Kosebay D and Erkun E: What should be the cut-off level of serum CA125 to evaluate the disease status before second-look laparotomy in epithelial ovarian carcinoma? Int J Gynecol Cancer 7(1): 42-5, 1997.
26. Bell R, Petticrew M and Sheldon T: The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 105(11): 1136-47, 1998.
27. Berek JS and Bast RC Jr: Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 76(10 Suppl): 2092-6, 1995.
28. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC and Jacobs IJ: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21(10 Suppl): 206-10, 2003.
29. Bast RC Jr, Klug TL, St. John E et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med 309(15): 883-887, 1983.
30. O'Connell GH, Ryan E, Murphy KJ and Prefontaine M: Predictive value of CA125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 70: 930-2, 1987.
31. Urban N, Drescher C, Etzioni R and Colby U: Use of a stochastic simulation model to identify an efficient strategy for ovarian cancer screening. Control Clin Trials 18: 251-70, 1997.
32. Carlson KJ, Skates SJ and Singer DE: Screening for ovarian cancer. Ann Intern Med 121(2): 124-132, 1994.
33. Jacobs I: Overview: progress in screening for ovarian cancer. In: Sharp F, Blackett A, Berek J, Bast R, ed. Ovarian Cancer 5. Oxford: Isis Medical Media, 1998.
34. Cohen LS, Escobar PF, Scharm C, Glimco B and Fishman DA: Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82: 40-48, 2001.
35. Van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ and Kryscio RJ: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77(3): 350-6, 2000.
36. De Priest PD: Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 65: 408-14, 1997.
37. Sehouli J, Akdogan Z, Heinze T, Konsgen D, Stengel D. Mustea A and Lichtenegger W: Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res 23(2A): 1115-8, 2003.
38. Yeh LS, Hung YC, Kao A, Linn CC and Lee CC: Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA125) in the early prediction of recurrent ovarian cancer. Anticancer Res 22(6B): 3669-71.
39. Chakravarti, Laha and Roy: Handbook of Methods of Applied Statistics, Volume 1, John Wiley and Sons, 1967 pp.392-394.